PO.CL07.01 · 临床研究
探索枣(Ziziphus jujuba)植物化学成分抗口腔癌作用:基于网络的分析与分子动力学研究
Exploring Ziziphus jujuba phytochemicals against oral cancer: Network-based profiling and molecular dynamics analyses
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
口腔癌因其复杂的分子异质性、有限的治疗疗效和高复发率,仍是全球重大的健康挑战。本研究旨在采用综合计算方法,鉴定源自枣(Ziziphus jujuba)的潜在多靶点天然治疗剂。采用网络药理学方法绘制与口腔致癌通路相关的植物化学成分-靶点相互作用图谱,重点关注EGFR、BCL2、SRC、STAT3和CTNNB1。进行分子对接以评估结合亲和力,随后进行200 ns分子动力学模拟和MM-GBSA分析,以评估复合物的稳定性和能量学特征。在所筛选的化合物中,齐墩果酮酸(oleanonic acid)表现出最有利的相互作用特征,其与BCL2的对接得分约为-9.0 kcal/mol,与EGFR约为-9.3 kcal/mol,优于参照抑制剂。MD轨迹显示稳定的RMSD平台期、较低的活性位点RMSF以及一致的Rg和SASA曲线,反映出稳健的配体-受体稳定性。MM-GBSA结果显示范德华力和疏水作用对复合物稳定化起主导贡献。总体而言,这些发现凸显齐墩果酮酸为一种源自枣的、具有潜在口腔癌治疗价值的有前景的多靶点植物化学成分。有必要进一步开展体外和体内研究,以验证这些计算预测并推进其作为口腔癌治疗候选药物的开发。
查看英文原文 English abstract
Oral cancer remains a major global health challenge due to its complex molecular heterogeneity, limited therapeutic efficacy, and high recurrence rate. This study aimed to identify potential multi-target natural therapeutics derived from Ziziphus jujuba using an integrative computational approach. Network pharmacology was employed to map phytochemical-target interactions relevant to oral oncogenic pathways, focusing on EGFR, BCL2, SRC, STAT3, and CTNNB1. Molecular docking was performed to evaluate binding affinities, followed by 200 ns molecular dynamics simulations and MM-GBSA analyses to assess complex stability and energetics. Among the screened compounds, oleanonic acid demonstrated the most favorable interaction profile, with docking scores of approximately -9.0 kcal/mol for BCL2 and -9.3 kcal/mol for EGFR, outperforming reference inhibitors. MD trajectories indicated stable RMSD plateaus, low active-site RMSF, and consistent Rg and SASA profiles, reflecting robust ligand-receptor stability. MM-GBSA results revealed dominant van der Waals and hydrophobic contributions to complex stabilization. Collectively, these findings highlight oleanonic acid as a promising multi-target phytochemical from Z. jujuba with potential therapeutic relevance in oral cancer. Further in vitro and in vivo studies are warranted to validate these computational predictions and advance its development as a candidate for oral cancer management.
利益披露 Disclosure
A. A. Assiri, None..
A. Alamri, None..
N. Khan, None.